0001567619-21-010772.txt : 20210520
0001567619-21-010772.hdr.sgml : 20210520
20210520143941
ACCESSION NUMBER: 0001567619-21-010772
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210503
FILED AS OF DATE: 20210520
DATE AS OF CHANGE: 20210520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38670
FILM NUMBER: 21943980
BUSINESS ADDRESS:
STREET 1: 1350 OLD BAYSHORE HIGHWAY
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 1350 OLD BAYSHORE HIGHWAY
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
FORMER NAME:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER NAME:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Innoviva Strategic Opportunities LLC
CENTRAL INDEX KEY: 0001842875
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38670
FILM NUMBER: 21943979
BUSINESS ADDRESS:
STREET 1: 1209 ORANGE STREET
CITY: WILMINGTON
STATE: DE
ZIP: 19801
BUSINESS PHONE: 877 202 1097
MAIL ADDRESS:
STREET 1: 1209 ORANGE STREET
CITY: WILMINGTON
STATE: DE
ZIP: 19801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc.
CENTRAL INDEX KEY: 0001724344
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824592913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 810-0120
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Entasis Therapeutics Ltd
DATE OF NAME CHANGE: 20171204
4
1
doc1.xml
FORM 4
X0306
4
2021-05-03
0
0001724344
Entasis Therapeutics Holdings Inc.
ETTX
0001080014
Innoviva, Inc.
1350 OLD BAYSHORE HIGHWAY SUITE 400
BURLINGAME
CA
94010
0
0
1
0
0001842875
Innoviva Strategic Opportunities LLC
1350 OLD BAYSHORE HIGHWAY SUITE 400
BURLINGAME
CA
94010
1
0
1
0
Common Stock
2021-05-03
4
P
0
3731025
2
A
3731025
I
See Footnote
Common Stock
18672897
D
Warrants to Purchase Common Stock
2.00
2021-05-03
4
P
0
3731025
2.00
A
2021-05-03
2026-05-03
Common Stock
3731025
3731025
I
See footnote
Warrants to Purchase Common Stock
Common Stock
18672897
18672897
D
As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva, Inc. ("INVA") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA ("ISO" and together with INVA, the "Reporting Persons") with the U.S. Securities and Exchange Commission on May 3, 2021 (the "Schedule 13D/A"), in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the "Purchase Agreement" and, such closing, the "Closing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and ISO, ISO acquired 3,731,025 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 3,731,025 Shares ("Warrants" and together with the Shares, the "Security") for an aggregate price of $2.00 per Security as set forth in this Form 4.
INVA acquired an aggregate of 18,672,897 shares of common stock of the issuer and warrants to purchase an aggregate 18,672,897 shares of common stock of the Issuer in transactions on April 22, 2020, June 11, 2020 and September 1, 2020.
INNOVIVA, INC. By: /s/ Pavel Raifeld
2021-05-03
INNOVIVA STRATEGIC OPPORTUNITIES LLC, By: Innoviva, Inc., its managing member, /s/ Pavel Raifeld
2021-05-03